SCHEMBL29907406

SCHEMBL29907406

CCOC(=O)c1cc(C(=O)Nc2ccc(OC(F)F)cc2)c(=O)n(-c2ccccc2OCC(F)(F)F)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UGCG Q16739 5/20 0.52
SMN1; SMN2 Q16637 1/20 0.44
ALDH1A1 P00352 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
MAPT P10636 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
MAPK1 P28482 1/20 0.38
PTPN7 P35236 1/20 0.38
RECQL P46063 1/20 0.38
DUSP3 P51452 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
NR3C1 P04150 1/20 0.38
LMNA P02545 1/20 0.37
PAX8 Q06710 1/20 0.37
P2RY1 P47900 3/20 0.37
KDR P35968 1/20 0.37
SCN9A Q15858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29601498 0.91 UGCG (0.55) UGCGSMN1; SMN2ALDH1A1NPSR1MAPT
SCHEMBL29907503 0.85 UGCG (0.60) UGCGSMN1; SMN2ALDH1A1NPSR1MAPT
SCHEMBL29907396 0.85 UGCG (0.54) UGCGSMN1; SMN2ALDH1A1NPSR1MAPT
SCHEMBL29907514 0.82 UGCG (0.45) UGCGMAPTKMT2APOLBMAPK1
SCHEMBL29907410 0.76 UGCG (0.75) UGCGSMN1; SMN2MAPTNR3C1P2RY1
SCHEMBL29601644 0.74 KMT2A (0.49) UGCGSMN1; SMN2ALDH1A1MAPTMEN1
SCHEMBL29907490 0.74 UGCG (0.75) UGCGSMN1; SMN2MAPTNR3C1P2RY1
SCHEMBL29601938 0.73 SMN1; SMN2 (0.42) UGCGSMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL29907407 0.73 UGCG (0.61) UGCGSMN1; SMN2ALDH1A1MAPTLMNA
SCHEMBL29907671 0.71 UGCG (0.48) UGCGSCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220289679-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220289679-A1 HETEROCYCLIC COMPOUND GBA1, GBA2, GALC UGCG 10/4885SMN1; SMN2 71/4885ALDH1A1 1563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.